Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liangxue Shugan Fang with Tamoxifen in ER-positive Postoperative Breast Cancer
ChiCTR-IPR-16008966Phase 4Recruiting
- Sponsor
- Shanghai Municipal Hospital of Traditional Chinese Medicine
- Start
- Aug 2016
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of liangxue shugan fang and tamoxifen in estrogen receptor-positive breast cancer (2 arms), sponsored by Shanghai Municipal Hospital of Traditional Chinese Medicine. Primary endpoint: Endometrial thickness. Started Aug 2016; status: recruiting.
02
Drugs
liangxue shugan fangtamoxifen
03
Conditions
estrogen receptor-positive breast cancer
Beyond the preview
Go deeper on ChiCTR-IPR-16008966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008966.